New hope for kidney patients: dapagliflozin trial targets slowing disease

NCT ID NCT06610526

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing the drug dapagliflozin in 731 Chinese adults with chronic kidney disease. The goal is to see if the drug can slow kidney decline and is safe. Participants take the drug by mouth, and researchers track kidney function and side effects over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin (a drug taken by mouth that helps protect the kidneys)
What this could lead to: If it works, this could provide a new treatment option to slow kidney disease progression in Chinese patients.
What could go wrong: This is a single-arm, open-label study without a placebo group, so results may be less reliable. It is also limited to Chinese adults, so findings may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE

Contacts and locations

Locations

Research Site

Beijing, 100034, China
Research Site

Beijing, 100044, China
Research Site

Beijing, 100068, China
Research Site

Beijing, 100191, China
Research Site

Beijing, 102206, China
Research Site

Changchun, 130021, China
Research Site

Dongguan, 523059, China
Research Site

Foshan, 528308, China
Research Site

Fuyang, 236012, China
Research Site

Fuzhou, 350001, China
Research Site

Ganzhou, 341099, China
Research Site

Harbin, 150000, China
Research Site

Hefei, 230601, China
Research Site

Hengyang, 421001, China
Research Site

Huaian, 223399, China
Research Site

Huizhou, 516001, China
Research Site

Jilin City, 132011, China
Research Site

Jinan, 250014, China
Research Site

Jining, 272029, China
Research Site

Lanzhou, 730000, China
Research Site

Linyi, 276199, China
Research Site

Nanchang, 330006, China
Research Site

Nanjing, 210029, China
Research Site

Nanning, 530021, China
Research Site

Ningbo, 315010, China
Research Site

Shanghai, 200090, China
Research Site

Shenzhen, 518036, China
Research Site

Suzhou, 215004, China
Research Site

Taian, 271099, China
Research Site

Tianjin, 300121, China
Research Site

Wuhu, 241000, China
Research Site

Wuxi, 214023, China
Research Site

Xi'an, 710000, China
Research Site

Xiamen, 361004, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.